The animal literature is unusually consistent, though: nearly every published in vivo study used 5 mg/kg per injection, given three times on alternate days (days 1, 3, and 5, or days 14, 16, and 18 in the pulmonary fibrosis model), with effects tracked over the following three to four weeks
BPC-157 in orthopaedic medicine
For I have 3 three questions: 1) Have you seen a way to equate dosages between oral form and subcutaneous injection to help determine what dosages correspond to each form
Lab and animal studies build on this as well, showing the extract reduces inflammatory signals, boosts a protein important for barrier health (filaggrin), and has anti-itch/antibacterial activity (including against C.acnes, the bacteria linked to breakouts)
This comprehensive review examines BPC-157s mechanisms of action, stability profile, and therapeutic applications across multiple organ systems